刘培庆,博士,教授,博士生导师,药理与毒理学实验室主任,新药研究开发中心主任,广东省新药成药性评估及评价工程实验室主任,广州市生物活性化合物成药性评价重点实验室主任。主要从事心血管药理学及分子生物学研究,研究方向为高血压心肌肥大的信号转导机制、比较蛋白质组学、动脉粥样硬化的发病机制及相关新药研究。先后主持国家自然科学基金6项、科技部“重大新药创制”科技重大专项2项、广东省自然科学基金团队项目1项、广东省自然科学基金重点项目2项,教育部重点项目及广东省市重点重大项目9项。近年来发表SCI论文70多篇(通讯作者50多篇,通讯作者论文累计影响因子超过150)、国家核心期刊论文60多篇,参编专著5部,为《中华现代内科学杂志》常务编委、《Oncogene》等审稿人。现任中国药理学会理事、广东省药理学会常务理事兼药物筛选与评价专业委员会主任委员、广东省人事厅博士后研究人员联谊会理事长、中国心血管药理学会、中国抗炎免疫药理学会等专业委员会委员等。担任国家自然科学基金审评专家、教育部博士点基金二审专家、广东省市科技项目及新药审评专家等,并被评为改革开放三十年广东省突出贡献专家。获得广东省科学技术一等奖(主要成员)以专利发明人或主要成员申请国家发明专利16项,其中12项已获授权。负责研发一种抗老年性痴呆药物已经完成临床前试验,进入临床申请阶段。指导博士研究生36名,22名已毕业并全部获得博士学位。指导的研究生获得了羊城学者、国家奖学金等荣誉。 联系方式:电 话:020-39943026, Email:liupq@mail.sysu.edu.cn ――――――――――――――――――――――――――――――――――――― Peiqing Liu, Director and Professor in Laboratory of Pharmacology & Toxicology, School of Pharmaceutical Science, Sun Yat-Sen University (SYSU). Until now, he has worked in the field of cardiovascular pharmacology and molecular biology for over 20 years, particularly in signal transduction,interaction between transcriptional factors and proteomic analysis in myocardial hypertrophy. He has published more than 130 research articles among which over 70 entered SCI, EI, ISTP, and is co-writer of 5 published monographs. As the director of New Drug R&D Center, he has established an advanced new drug evaluation and screening system and constructed a serial of new drug targets. His work was recognized by the SYSU and government, and two laboratories under his leadership, Guangdong Provincial Engineering Laboratory of Druggability Assessment and Evaluation, and Guangzhou Key Laboratory of Druggability Assessment for Biologically Active Compounds have been approved by Guangdong Province and Guangzhou City government. His research programs are supported by National Natural Science Foundation of China (NSFC), the National Science and Technology Major Project of China “Key New Drug Creation and Manufacturing Program”, Team Item of Natural Science Foundation of Guangdong Province, etc. Recently, He has also completed a new drug’s R&D for the treatment of Alzheimer’s disease in response to a program launched by the Ministry of Health of China. Contact: Phone: 020-39943026 ; Email: liupq@mail.sysu.edu.cn Publication: [1] Zhou SG, Zhou SF ,Huang HQ, Chen JW, Huang M, Liu PQ (Corresponding author). Proteomic Analysis of Hypertension-Induced Left Ventricular Hypertrophy by Two-Dimensional Difference Gel Electrophoresis and Mass Spectrometry. J Proteome Res, 2006, 5(11):2901-2908. SCI, IF: 6.919. [2] Xu S, Ogura S, Chen J, Little PJ, Moss J, Liu P (Corresponding author). LOX-1 inatherosclerosis:biological functions and pharmacological modifiers. Cell Mol Life Sci. 2012 Nov3. [Epub ahead of print] PubMed PMID: 23124189. SCI, IF: 6.570. [3] Yu SS, Cai Y, Ye JT, Pi RB, Chen SR, Liu PQ (Corresponding author) Shen XY, Ji Y. Sirtuin 6 protects cardiomyocytes from hypertrophy in vitro via inhibition of NF-kappaB-dependent transcriptional activity, Br J Pharmacol, Br J Pharmacol. 2013 Jan;168(1):117-28. SCI, IF: 4.925. [4] Chen Y, Wang Y, Chen J, Chen X, Cao W, Chen S, Xu S, Huang H, Liu PQ (Corresponding author). Roles of transcriptional corepressor RIP140 and coactivator PGC-1α in energy state of chronically infarcted rat hearts and mitochondrial function of cardiomyocytes, Mol Cell Endocrinol. 2012 Oct 15;362(1-2):11-8SCI, IF: 4.119. [5] Gao S, Liu Z, Li H, Little PJ, Liu PQ (Corresponding author), Xu S. Cardiovascular actions and therapeutic potential of tanshinone IIA, Atherosclerosis, 2012, 220: 3-10. SCI, IF: 4.086. [6] Cai Y, Yu SS, Chen SR, Pi RB, Gao S, Li H, Ye JT, Liu PQ (Corresponding author). Nmnat2 protects cardiomyocytes from hypertrophy via activation of SIRT6. FEBS Lett. 2012 Mar 23;586(6):866-74. SCI, IF: 3.538. [7] Wang P, Zhou S, Xu L, Lu Y, Yuan X, Zhang H, Li R, Fang J, Liu P Liu PQ (Corresponding author). Hydrogen peroxide-mediated oxidative stress and collagen synthesis in cardiac fibroblasts: Blockade by tanshinone IIA. J Ethnopharmacol. 2013 Jan 9;145(1):152-61 (IF: 3.728) [8] Cai Y, Yu SS, Chen TT, Gao S, Geng B, Yu Y, Ye JT, Liu PQ (Corresponding author). EGCG inhibits CTGF expression via blocking NF-κB activation in cardiac fibroblast. Phytomedicine. 2012. 20(2):106-13. SCI, IF: 3.300. [9] Le K, Li R, Xu S, Wu X, Huang H, Bao Y, Cai Y, Lan T, Moss J, Li C, Zou J, Shen X, Liu PQ(Corresponding author). PPARalpha activation inhibits endothelin-1-induced cardiomyocyte hypertrophy by prevention of NFATc4 binding to GATA-4, Arch Biochem Biophys, 2012, 518: 71-78. SCI, IF:3.022. [10] Xu S, Liu Z, Huang Y, Le K, Tang F, Huang H, Ogura S, Little PJ, Shen X, Liu PQ (Corresponding author). Tanshinone II-A inhibits oxidized LDL-induced LOX-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-κB activation, Transl Res, 2012. Online published. SCI,IF: 2.903. [11] Mei Z, Yan P, Situ B, Mou Y, Liu PQ (Corresponding author). Cryptotanshinione Inhibits beta-Amyloid Aggregation and Protects Damage from beta-Amyloid in SH-SY5Y Cells, Neurochem Res, 2012, 37: 622-628. SCI, IF: 2.608. [12] Chen W, Tang F, Xie B, Chen S, Huang H, Liu PQ (Corresponding author). Amelioration of atherosclerosis by tanshinone IIA in hyperlipidemic rabbits through attenuation of oxidative stress, Eur J Pharmacol, 2012, 674: 359-364. SCI, IF: 2.737. [13] Tang W, Wei Y, Le K, Li Z, Bao Y, Gao J, Zhang F, Cheng S, Liu P (Corresponding author). Mitogen-activated protein kinases ERK 1/2- and p38-GATA4 pathways mediate the Ang II-induced activation of FGF2 gene in neonatal rat cardiomyocytes. Biochemical Pharmacology 2011. 81: 518-525. SCI, IF: 4.899. [14] Wang CZ, Zhang Y, Li XD, Hu Y, Fang ZG, Lin DJ, Xiao RZ, Huang RW, Huang HQ, Liu PQ (Corresponding author), Liu JJ. PPARγ agonist suppresses TLR4 expression and TNF-α production in LPS stimulated monocyte leukemia cells. Cell Biochem Biophys. Cell Biochem Biophys. 2011;60(3):167-72. SCI, IF: 4.312. [15] Xu S, Little PJ, Lan T, Huang Y, Le K, Wu X, Shen X, Huang H, Cai Y, Tang F, Wang H, Liu PQ(Corresponding author). Tanshinone II-A attenuates and stabilizes atherosclerotic plaques in apolipoprotein-E knockout mice fed a high cholesterol diet, Arch Biochem Biophys, 2011, 515: 72-79.SCI, IF: 3.022. [16] Xu S, Liu PQ (Corresponding author). Tanshinone II-A: new perspectives for old remedies. Expert Opin Ther Pat. 2013 Feb;23(2):149-53 IF: 3.57 [17] Geng B, Cai Y, Gao S, Lu J, Zhang L, Zou J, Liu M, Yu S, Ye J, Liu PQ (Corresponding author). PARP-2 knockdown protects cardiomyocytes from hypertrophy via activation of SIRT1.Biochem Biophys Res Commun. 2013 Jan 18;430(3):944-50 IF:2.52 [18] Tang FT, Cao Y, Wang TQ, Wang LJ, Guo J, Zhou XS, Xu SW, Liu WH, Liu PQ (Corresponding author),Huang HQ. Tanshinone IIA attenuates atherosclerosis in ApoE(-/-) mice through down-regulation of scavenger receptor expression. Eur J Pharmacol. 2011 ;650(1):275-84. SCI, IF: 2.737. [19] Tang S, Shen XY, Huang HQ, Xu SW, Yu Y, Zhou CH, Chen SR, Le K, Wang YH, Liu PQ (Corresponding author). Cryptotanshinone suppressed inflammatory cytokines secretion in RAW264.7 macrophages through inhibition of the NF-kappaB and MAPK signaling pathways, Inflammation, 2011, 34: 111-118. [20] Wang P, Wu X, Bao Y, Fang J, Zhou S, Gao J, Pi R, Mou YG, Liu PQ (Corresponding author). Tanshinone IIA prevents cardiac remodeling through attenuating NAD(P)H oxidase-derived reactive oxygen species production in hypertensive rats, Pharmazie, 2011, 66: 517-524. [21] Wu X, Huang H, Tang F, Le K, Xu S, Liu PQ (Corresponding author). Regulated Expression of Endothelial Lipase in Atherosclerosis. Mol Cell Endocrinol. 2010 Feb 5;315(1-2):233-238. SCI, IF: 3.611. [22] Mei Z, Situ B, Tan X, Zheng S, Zhang F, Yan P, Liu PQ (Corresponding author). Cryptotanshinione upregulates alpha-secretase by activation PI3K pathway in cortical neurons, Brain Res, 2010, 1348: 165-173. SCI, IF: 2.623. [23] Fang J, Xu SW, Wang P, Tang FT, Zhou SG, Gao J, Chen JW, Huang HQ, Liu PQ (Corresponding author). Tanshinone II-A attenuates cardiac fibrosis and modulates collagen metabolism in rats with renovascular hypertension, Phytomedicine, 2010, 18: 58-64. SCI, IF: 2.223. [24] Chen SR, Xu XZ, Wang YH, Chen JW, Xu SW, Gu LQ, Liu PQ (Corresponding author). Icariin derivative inhibits inflammation through suppression of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, Biol Pharm Bull, 2010, 33: 1307-1313. SCI, IF: 2.021. [25] Chen SR, Xu XZ, Wang YH, Chen JW, Xu SW, Gu LQ, Liu PQ (Corresponding author). Aspirin increases apolipoprotein-A-I-mediated cholesterol efflux via enhancing expression of ATP-binding cassette transporter A1, Pharmacology, 2010, 86: 320-326. [26] Xu S, Huang Y, Xie Y, Lan T, Le K, Chen J, Chen S, Gao S, Xu X, Shen X, Huang H, Liu PQ(Corresponding author). Evaluation of foam cell formation in cultured macrophages: an improved method with Oil Red O staining and DiI-oxLDL uptake, Cytotechnology, 2010, 62: 473-481. [27] Liu W, Tang F, Deng Y, Li X, Lan T, Zhang X, Huang H, Liu PQ (Corresponding author). Berberine reduces fibronectin and collagen accumulation in rat glomerular mesangial cells cultured under high glucose condition, Mol Cell Biochem, 2009, 325: 99-105. SCI, IF: 3.611. [28] Zhang F, Zheng W, Pi R, Mei Z, Bao Y, Gao J, Tang W, Chen S, Liu PQ (Corresponding author). Cryptotanshinone protects primary rat cortical neurons from glutamate-induced neurotoxicity via the activation of the phosphatidylinositol 3-kinase/Akt signaling pathway, Exp Brain Res, 2009, 193: 109-118. SCI, IF: 2.46. [29] Ye JT, Pi RB, Mao XX, Chen XH, Qin J, Xu SW, Liu PQ (Corresponding author). Alterations in mRNA expression of BACE1, cathepsin B, and glutaminyl cyclase in mice ischemic brain, Neuroreport, 2009, 20: 1456-1460. SCI, IF: 2.195. [30] Cao Y, Wang Z, Bu X, Tang S, Mei Z, Liu PQ (Corresponding author). A synthetic peptide derived from A1 module in CRD4 of human TNF receptor-1 inhibits binding and proinflammatory effect of human TNF-alpha. Inflammation. 2009 Jun;32(3):139-45. [31] Xu S, Fu J, Chen J, Xiao P, Lan T, Le K, Cheng F, He L, Shen X, Huang H, Liu PQ (Corresponding author). Development of an optimized protocol for primary culture of smooth muscle cells from rat thoracic aortas, Cytotechnology, 2009, 61: 65-72. [32] Wang Z, Cao Y, Shen X, Bu X, Bao Y, Le K, Mei Z, Tang S, Yu S, Liu PQ (Corresponding author). Inhibition of endothelin converting enzyme-1 activity or expression ameliorates angiotensin II-induced myocardial hypertrophy in cultured cardiomyocytes, Pharmazie, 2009, 64: 755-759. [33] Tang W, Pan Q, Sun F, Ma J, Tang S, Le K, Wan Y, Chen Q, Liu PQ (Corresponding author). Involvement of Sp1 binding sequences in basal transcription of the rat fibroblast growth factor-2 gene in neonatal cardiomyocytes, Life Sci, 2009, 84: 421-427. SCI, IF: 2.661. [34] Mei Z, Zhang F, Tao L, Zheng W, Cao Y, Wang Z, Tang S, Le K, Chen S, Pi R, Liu PQ (Corresponding author). Cryptotanshinone, a compound from Salvia miltiorrhiza modulates amyloid precursor protein metabolism and attenuates beta-amyloid deposition through upregulating alpha-secretase in vivo and in vitro, Neurosci Lett, 2009, 452: 90-95. SCI, IF: 2.455. [35] Zhou SG, Wang P, Pi RB, Gao J, Fu JJ, Fang J, Qin J, Zhang HJ, Li RF, Chen SR, Tang FT, Liu PQ(Corresponding author). Reduced expression of GSTM2 and increased oxidative stress in spontaneously hypertensive rat. Mol Cell Biochem,2008,309(1-2):99-107. SCI, IF: 2.168. [36] Gao J, Yang G, Pi R, Li R, Wang P, Zhang H, Le K, Chen S, Liu PQ (Corresponding author). Tanshinone IIA protects neonatal rat cardiomyocytes from adriamycin-induced apoptosis. Transl Res. 2008,151(2):79-87. SCI, IF: 2.658. [37] Bao Y, Li R, Jiang J, Cai B, Gao J, Le K, Zhang F, Chen S, Liu PQ (Corresponding author). Activation of peroxisome proliferator-activated receptor gamma inhibits endothelin-1-induced cardiac hypertrophy via the calcineurin/NFAT signaling pathway. Mol Cell Biochem. 2008 Oct;317(1-2):189-96. SCI, IF: 2.168. [38] Li R, Zheng W, Pi R, Gao J, Zhang H, Wang P, Le K, Liu PQ (Corresponding author). Activation of peroxisome proliferator-activated receptor-alpha prevents glycogen synthase 3beta phosphorylation and inhibits cardiac hypertrophy. FEBS Lett. 2007 Jul 10;581(17):3311-6. SCI, IF: 3.52. [39] Zhang H, Pi R, Li R, Wang P, Tang F, Zhou S, Gao J, Jiang J, Chen S, Liu PQ (Corresponding author).PPARβ/δ activation inhibits angiotensin II-induced collagen type I expression in rat cardiac fibroblasts.Arch Biochem Biophys. 2007,460(1):25-32. SCI, IF: 3.012. [40] Wang P, Tang F, Li R, Zhang H, Chen S, Liu PQ (Corresponding author), Huang H. Contribution of Different Nox Homologues to Cardiac Remodeling in Two-Kidney Two-Clip Renovascular Hypertensive Rats: Effect of Valsartan. Pharmacol Res, 2007, 55(05): 408-417. SCI, IF: 2.421. [41] Tang F, Wu X, Wang T, Wang P, Li R, Zhang H, Gao J, Chen S, Bao L, Huang H, Liu PQ (Corresponding author). Tanshinone II A attenuates atherosclerotic calcification in rat model by inhibition of oxidative stress. Vascul Pharmacol. 2007;46(6):427-38. [42] Liu JJ, Liu PQ (Corresponding author), Lin DJ, Xiao RZ, Huang M, Li XD, He Y, Huang RW. Downregulation of cyclooxygenase-2 expression and activation of caspase-3 are involved in peroxisome proliferator-activated receptor-gamma agonists induced apoptosis in human monocyte leukemia cells in vitro. Ann Hematol. 2007 Mar;86(3):173-183. SCI, IF: 2.254. [43] Fu J, Huang H, Liu J, Pi R, Chen J, Liu PQ (Corresponding author). Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. Eur J Pharmacol. 2007;568(1-3):213-21. SCI收录, IF: 2.524. [44] Tang FT, Liu PQ (Corresponding author), Wu XQ,Wang, TQ. Hypercholesterolemia Accelerates Vascular Calcification Induced by Excessive Vitamin D via Oxidative Stress. Calcified Tissue International: 2006: 79: 326-339. SCI, IF: 2.46. [45] Wang J, Huang H, Liu PQ (Corresponding author), Tang F, Qin J, Huang W, Chen F, Guo F, Liu W, Yang B. Inhibition of phosphorylation of p38 MAPK involves in protection of nephropathy by Emodin in diabetic rats. Eur J Pharmacol, 2006,553:297-303. SCI, IF: 2.45. Co-write Articles in last 5 years [1] Sisi Lin, Chun Zhou, Edward Neufeld, Yu-Hua Wang, Suo-Wen Xu, Liang Lu, Ying Wang, Zhi-Ping Liu, Dong Li, Cuixian Li, Shaorui Chen, Kang Le, Heqing Huang, Peiqing Liu, Joel Moss, Martha Vaughan, Xiaoyan Shen. BIG1, a brefeldin A-inhibited guanine nucleotide- exchange protein modulates ABCA1 trafficking and function. Arteriosclerosis, Thrombosis, and Vascular Biology. 2012 accepted. [2] Pi R, Mao X, Chao X, Cheng Z, Liu M, Duan X, Ye M, Chen X, Mei Z, Liu P, Li W, Han Y. Tacrine-6-ferulic acid, a novel multifunctional dimer, inhibits amyloid-β-mediated Alzheimer's disease-associated pathogenesis in vitro and in vivo. PLoS One. 2012;7(2):e31921. [3] Meng F, Hou J, Shao YX, Wu PY, Huang M, Zhu X, Cai Y, Li Z, Xu J, Liu P, Luo HB, Wan Y, Ke H. Structure-Based Discovery of Highly Selective Phosphodiesterase-9A Inhibitors and Implications for Inhibitor Design. J Med Chem. 2012 Oct 11;55(19):8549-58. doi: 10.1021/jm301189. [4] Wang H, Duan X, Ren Y, Liu Y, Huang M, Liu P, Wang R, Gao G, Zhou L, Feng Z, Zheng W. FoxO3aNegatively Regulates Nerve Growth Factor-Induced Neuronal Differentiation Through Inhibiting the Expression of Neurochondrin in PC12 Cells. Mol Neurobiol. 2012 Oct 21. [Epub ahead of print]. [5] Huang J, Huang K, Lan T, Xie X, Shen X, Liu P, Huang H. Curcumin ameliorates diabetic nephropathy by inhibiting the activation of the SphK1-S1P signaling pathway. Mol Cell Endocrinol. 2012 Nov 2. doi:pii: S0303-7207(12)00476-5. [6] Lan T, Liu W, Xie X, Huang K, Peng J, Huang J, Shen X, Liu P, Yang H, Huang H. Berberine suppresses high glucose-induced TGF-β1 and fibronectin synthesis in mesangial cells through inhibition of sphingosine kinase 1/AP-1 pathway. Eur J Pharmacol. 2012 Dec 15;697(1-3):165-7. [7] Huang K, Liu W, Lan T, Xie X, Peng J, Huang J, Wang S, Shen X, Liu P, Huang H. Berberine reduces fibronectin expression by suppressing the S1P-S1P2 receptor pathway in experimental diabetic nephropathy models. PLoS One. 2012;7(8):e43874. doi: 10.1371/journal.pone.0043874. [8] Lin W, Wang Y, Lin ., Li C, Zhou C, Wang S, Huang H, Liu P, Ye G and Shen X. Induction of cell cycle arrest by the carbazole alkaloid Clauszoline-I from Clausena vestita D. D. Tao via inhibition of the PKCdelta phosphorylation, Eur J Med Chem, 2012, 47: 214-220. [9] Xie X, Peng J, Huang K, Huang J, Shen X, Liu P, Huang H. Polydatin ameliorates experimental diabetes-induced fibronectin through inhibiting the activation of NF-κB signaling pathway in rat glomerular mesangial cells. Mol Cell Endocrinol. 2012 Oct 15;362(1-2):183-93. [10] Li Y, Wang S, Wang Y, Zhou C, Chen G, Shen W, Li C, Lin W, Lin S, Huang H, Liu P, Shen X. Inhibitory effect of the antimalarial agent artesunate on collagen-induced arthritis in rats through nuclear factor kappa B and mitogen-activated protein kinase signaling pathway. Transl Res. 2012 Jun 29. [Epub ahead of print]. [11] Xie X, Li W, Lan T, Liu W, Peng J, Huang K, Huang J, Shen X, Liu P and Huang H. Berberine ameliorates hyperglycemia in alloxan-induced diabetic C57BL/6 mice through activation of Akt signaling pathway. Endocr J. 2011, 58: 761-768. [12] Mao X, Yin W, Liu M, Ye M, Liu P, Liu J, Lian Q, Xu S and Pi R. Osthole, a natural coumarin, improves neurobehavioral functions and reduces infarct volume and matrix metalloproteinase-9 activity after transient focal cerebral ischemia in rats. Brain Res, 2011, 1385: 275-280. [13] Lan, T., Liu, W., Xie, X., Xu, S., Huang, K., Peng, J., Shen, X., Liu, P., Wang, L., Xia, P. and Huang, H., Sphingosine kinase-1 pathway mediates high glucose-induced fibronectin expression in glomerular mesangial cells, Mol Endocrinol, 2011, 25: 2094-2105. [14] Li, C., Zhou, C., Wang, S., Feng, Y., Lin, W., Lin, S., Wang, Y., Huang, H., Liu, P., Mu, Y. G. and Shen, X., Sensitization of glioma cells to tamoxifen-induced apoptosis by Pl3-kinase inhibitor through the GSK-3beta/beta-catenin signaling pathway, PLoS One, 2011, 6: e27053. [15] Jiang, Q., Liu, P., Wu, X., Liu, W., Shen, X., Lan, T., Xu, S., Peng, J., Xie, X. and Huang, H., Berberine attenuates lipopolysaccharide-induced extracelluar matrix accumulation and inflammation in rat mesangial cells: involvement of NF-kappaB signaling pathway, Mol Cell Endocrinol, 2011, 331: 34-40. [16] Wu, X., Cheng, J., Li, P., Yang, M., Qiu, S., Liu, P. and Du, J., Mechano-sensitive transcriptional factor Egr-1 regulates insulin-like growth factor-1 receptor expression and contributes to neointima formation in vein grafts, Arterioscler Thromb Vasc Biol, 2010, 30: 471-476. [17] Liu, W., Zhang, X., Liu, P., Shen, X., Lan, T., Li, W., Jiang, Q., Xie, X. and Huang, H., Effects of berberine on matrix accumulation and NF-kappa B signal pathway in alloxan-induced diabetic mice with renal injury, Eur J Pharmacol, 2010, 638: 150-155. [18] Liu, M., He, L., Hu, X., Liu, P. and Luo, H. B., 3D-QSAR, homology modeling, and molecular docking studies on spiropiperidines analogues as agonists of nociceptin/orphanin FQ receptor, Bioorg Med Chem Lett, 2010, 20: 7004-7010. [19] Lan, T., Shen, X., Liu, P., Liu, W., Xu, S., Xie, X., Jiang, Q., Li, W. and Huang, H., Berberine ameliorates renal injury in diabetic C57BL/6 mice: Involvement of suppression of SphK-S1P signaling pathway, Arch Biochem Biophys, 2010, 502: 112-120. [20] Chen, X. H., Lin, Z. Z., Liu, A. M., Ye, J. T., Luo, Y., Luo, Y. Y., Mao, X. X., Liu, P. Q. and Pi, R. B., The orally combined neuroprotective effects of sodium ferulate and borneol against transient global ischaemia in C57 BL/6J mice, J Pharm Pharmacol, 2010, 62: 915-923. [21] Wu, X. F., Wang, C. L., Xie, E. B., Gao, Y., Fan, Y. L., Liu, P. Q. and Zhao, K. J., Molecular cloning and characterization of the promoter for the multiple stress-inducible gene BjCHI1 from Brassica juncea, Planta, 2009, 229: 1231-1242. [22] Liu, J. J., Guo, Y. W., Fang, Z. G., Si, X. N., Wu, X. Y., Liu, P. Q., Lin, D. J., Xiao, R. Z., Xu, Y., Wang, C. Z., Li, X. D., He, Y. and Huang, R. W., Activation of peroxisome proliferator-activated receptor-gamma induces apoptosis on acute promyelocytic leukemia cells via downregulation of XIAP, Int J Mol Med, 2009, 24: 623-632. [23] Li, X., Liu, W., Wang, Q., Liu, P., Deng, Y., Lan, T., Zhang, X., Qiu, B., Ning, H. and Huang, H., Emodin suppresses cell proliferation and fibronectin expression via p38MAPK pathway in rat mesangial cells cultured under high glucose, Mol Cell Endocrinol, 2009, 307: 157-162. [24] Chen, X., Hu, X., Zou, Y., Pi, R., Liu, M., Wang, T., Zheng, X., Lin, M., Liu, P. and Tao, L., Combined treatment with minocycline and prednisone attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice, J Neuroimmunol, 2009, 210: 22-29. [25] Chen, X., Lan, X., Mo, S., Qin, J., Li, W., Liu, P., Han, Y. and Pi, R., p38 and ERK, but not JNK, are involved in copper-induced apoptosis in cultured cerebellar granule neurons, Biochem Biophys Res Commun, 2009, 379: 944-948. [26] Shen SH, Gu LJ, Liu PQ, Ye X, Chang WS, Li BS. Comparative proteomic analysis of differentially expressed proteins between K562 and K562/ADM cells. Chin Med J (Engl). 2008 Mar 5;121(5):463-8. [27] Pan Y, Bi HC, Zhong GP, Chen X, Zuo Z, Zhao LZ, Gu LQ, Liu PQ, Huang ZY, Zhou SF, Huang M. Pharmacokinetic characterization of hydroxylpropyl-beta-cyclodextrin-included complex of cryptotanshinone, an investigational cardiovascular drug purified from Danshen (Salvia miltiorrhiza). Xenobiotica. 2008;38(4):382-98. [28] Bi HC, Zuo Z, Chen X, Xu CS, Wen YY, Sun HY, Zhao LZ, Pan Y, Deng Y, Liu PQ, Gu LQ, Huang ZY, Zhou SF, Huang M. Preclinical factors affecting the pharmacokinetic behaviour of tanshinone IIA, an investigational new drug isolated from Salvia miltiorrhiza for the treatment of ischaemic heart diseases.Xenobiotica, 2008,38(2):185-222. [29] Liu W, Liu P, Tao S, Deng Y, Li X, Lan T, Zhang X, Guo F, Huang W, Chen F, Huang H, Zhou SF. Berberine inhibits aldose reductase and oxidative stress in rat mesangial cells cultured under high glucose. Arch Biochem Biophys. 2008 ;475(2):128-34. [30] Liu WH, Hei ZQ, Nie H, Tang FT, Huang HQ, Li XJ, Deng YH, Chen SR, Guo FF, Huang WG, Chen FY, Liu PQ. Berberine ameliorates renal injury in streptozotocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase. Chin Med J (Engl). 2008 Apr 20;121(8):706-12. 二、近五年已完成(或即将完成)的重大科研项目和取得的科研成果。 近五年主持科技部重大新药创制项目2项,已完成1项;主持国家自然科学基金5项,已完成3项。主持广东省自然科学基金团队项目及重点项目各1项,其中重点项目已完成。主持完成广东省科技计划重点项目1项、在研广州市重大科技计划项目及广东省教育厅重点项目各1项,具体如下: (一)作为负责人承担或完成的项目: 1、科技部重大新药创制十一五专项:“隐丹参酮作为防治老年性痴呆新药的临床前研究”,项目批准号:2009ZX09102-152,250万元。2009年1月-2010年12月,已申请结题,项目负责人 2、科技部重大新药创制十二五专项:“丹参酮ⅡA化合物作为治疗动脉粥样硬化新药的临床前研究”,项目批准号:2011ZX09401-307,100万元,2011年1月—2013年12月,项目负责人 3、国家自然科学基金面上项目(No. 81273499)转录辅助抑制因子RIP140在心力衰竭中的转录调控机制研究,80万元,2013年1月—2016年12月,项目负责人 4、国家自然科学基金“Sirt6调控心肌肥大的信号转导机制研究”,项目批准号81072641,38万元,2011年1月-2013年12月,项目负责人 5、国家自然科学基金中加合作计划,“TRPM7通道介导心脏成纤维细胞Ca2+信号机制研究”,项目批准号:30811120434,45万元,2009年1月—2011年12月,项目负责人,已结题 6、国家自然科学基金,“PPARα与NFATc4信号通路相互作用对心肌肥大的调控研究”,项目批准号:30772576,32万元,2008年1月—2010年12月,项目负责人,已结题 7、国家自然科学基金,人源性ECE-1c作为抗心肌肥大药物筛选靶标的构建及研究,项目批准号:30672459,30万元,2007年1月—2009年12月,项目负责人,已结题 8、广东自然科学基金研究团队项目,基于靶标磷酸二酯酶(PDEs)结构的先导物筛选及其临床前研究,项目批准号:S2011030003190,250万元,2011.01-2015.12,第一负责及协调人 9、广东省自然科学基金重点项目,“从核因子相互作用角度研究防治心肌肥大新的药物靶点”,项目批准号:7117380,20万元。2007年1月—2009年12月,项目负责人,已结题。 10、教育部高等学校博士学科点专项科研基金“人源性内皮素转化酶作为抗高血压心肌肥大药物筛选靶标的构建及研究”,项目批准号:20070558208,6万元。2007年1月—2009年12月,项目负责人,已结题。 11、广东省科技计划重大项目. 多靶点抑制剂W7作为防治老年性痴呆1类新药的临床前研究,100万,2013年1月—2015年12月,项目负责人 广东省科技计划重点项目 多肽类肿瘤坏死因子受体拮抗剂作为抗心衰新药的筛选及研发,2008年1月—2009年12月,项目负责人,已结题 12、广东省教育厅重点项目,“基于靶标磷酸二酯酶结构的先导物筛选体系建立及方法研究” 项目批准号:CXZD1006,40万元。2011年1月—2013年12月,项目负责人 13、广州市科技重大专项计划,“丹参酮IIA联合阿托伐他汀作为抗动脉粥样硬化复方新药的临床前研究及评价”,项目批准号:专项0641,45万元/年。2011年1月—2013年12月,项目负责人 14、广东省发改委体系建设项目,“广东省新药成药性评估及评价工程实验室”,2011年9月-2013年12月,建设经费2000万元,政府拨款100万元,实验室主任。 15、广州市科技局条件建设项目. “广州市生物活性化合物成药性评价重点实验室”,100万,2012年9月-2015年12月,政府拨款100万元,实验室主任。 (二)作为分题负责或主要成员完成的项目 1 科技部重大新药创制十一五专项 新药临床前药效学评价技术平台建设 2009ZX09303-007 1113万元;专项副组长(负责267万元) 2009年1月-2010年12月;完成 2 欧盟第七科技框架项目 有机催化方法合成易得、经济和高产的达菲及其衍生物 39.9万欧元;分题组长(负责40万元) 2009年1月-2011年12月;完成 3 粤港关键领域重点突破项目 (广东省发改委专项) 中药有效单体筛选评价及结构改造技术研发 500万元;第二主要成员 2008年1月-2011年12月;完成 4 国家自然科学基金重点项目(30730079/ C030103) 花色苷类植物化学物抗动脉粥样硬化效应及分子机制研究,第二主要成员,2008-2011 160万元,第二主要成员 2009年1月-2011年12月;完成 三、获奖及专利情况: (一)代表性专利 1、刘培庆等。中国发明专利授权。一种多肽及其在制备抗心衰和炎性反应药物中的应用;申请号, 200810218732.2,公开号CN101401930,授权号:ZL 200810218732.2;授权日:2010.12.29 2、 刘培庆等。中国发明专利公开实审。一种用于预防和治疗动脉粥样硬化的药物组合物,申请号201110073572.9,公开号CN102125567A,专利号: ZL 201110073572.9,授权时间:2012.11 3、黄河清,刘培庆等。中国发明专利授权。 一种治疗糖尿病的药物组合物及其制备方法,申请号200510101169.7,公开号 CN1813957,授权号:ZL 200510101169.7, 授权日2007.09.12,成功转让并已进入3期临床试验。 4、其他共同申请的专利(其中10项已授权) 序号 申请号 专利名称 1 01130086.8 丹参酮11A用于制备预防和治疗动脉粥样硬化的药物 2 200610037417.0 含紫杉醇的天然植物提取物的复方药物及其抗癌应用 3 200710031777.4 一种防治缺血性脑血管疾病的药物复合物及其制备方法 4 200410027181.3 治疗糖尿病及其血管并发症的药物及该药物的制备方法 5 200410027508.7 抗动脉粥样硬化症药物及其制备方法 6 200610034181.5 2,6-二吡啶烯环己酮衍生物及其在制备抗菌药物中的应用 7 200710026642.9 一种自动化滴定分析的方法及其应用 8 201110112881.2 吡唑并[3,4-d]嘧啶酮类化合物及其在制备磷酸二酯酶Ⅸ抑制剂中的应用 9 200710028609.X 隐丹参酮在制备防治自身免疫性疾病药中的应用 10 200810027401.0 一种红豆杉树可再生部分的提取物的制备方法及该提取物在制备口服抗癌药物中的应用 11 200810028558.5 他克林-阿魏酸杂联体,其制备方法及其药物组合物 12 200810028696.3 一种治疗溃疡性结肠炎的药物组合物及其制备方法 13 201110269084.5 羟基取代的黄酮类化合物及其制备方法和应用 (二)获奖情况 1、2010年广东省科学技术一等奖。基于天然产物结构改造的靶向性药物先导化合物的基础性研究。证书编号:B17-0-1-01-D01;获奖人:古练权;黄志纾;欧田苗;卜宪章;刘培庆;马林;黄世亮;安林坤;谭嘉恒; 卢宇靖;毕惠嫦。 2、2010年度高等学校科学研究优秀成果奖自然科学奖二等奖(教育部)。基于天然产物结构改造的靶向性药物先导化合物的基础性研究。证书编号:2010-100;获奖人:古练权;黄志纾;欧田苗;黄民;刘培庆;卜宪章;谭嘉恒;黄世亮;安林坤;马林;卢宇靖。
序号 名称
序号 名称   合作论文
1黄河清------------合作论文:69篇
2陈少锐------------合作论文:53篇
3Lu, Jing------------合作论文:37篇
4沈晓燕------------合作论文:35篇
5Suowen,Xu------------合作论文:34篇
6李卓明------------合作论文:34篇
7叶建涛------------合作论文:32篇
8皮荣标------------合作论文:27篇
9Wang, Panxia------------合作论文:24篇
10Huang, Kaipeng------------合作论文:19篇
11Gao, Si------------合作论文:19篇
12Li, Jingyan------------合作论文:19篇
13黄俊英------------合作论文:19篇
14Liu, Zhiping------------合作论文:18篇
15Wang, Junjian------------合作论文:15篇
16Chen, Jianwen------------合作论文:15篇
17蒋建敏------------合作论文:15篇
18Le, Kang------------合作论文:14篇
19Tang, Futian------------合作论文:14篇
20谢曦------------合作论文:14篇
序号 名称   论文数量
1医学------------论文:94篇
2药学------------论文:55篇
3理学------------论文:31篇
4生物学------------论文:22篇
5临床医学------------论文:21篇
6基础医学------------论文:18篇
7化学------------论文:5篇
序号 名称   论文数量
1MOL CELL ENDOCRINOL------------论文:18篇
2ACTA PHARMACOL SIN------------论文:15篇
3ARCH BIOCHEM BIOPHYS------------论文:13篇
4TRANSL RES------------论文:10篇
5EUR J PHARMACOL------------论文:9篇
6BIOCHEM PHARMACOL------------论文:8篇
7BRIT J PHARMACOL------------论文:6篇
8PHARMACOL RES------------论文:6篇
9J PHARMACOL SCI------------论文:6篇
10INT J CARDIOL------------论文:5篇
11PLOS ONE------------论文:4篇
12NEUROSCI LETT------------论文:4篇
13EXP CELL RES------------论文:4篇
14CYTOTECHNOLOGY------------论文:3篇
15CELL DEATH DIS------------论文:3篇
16BIOORG MED CHEM LETT------------论文:3篇
17FRONT PHARMACOL------------论文:3篇
18ACTA PHARMACOL SIN B------------论文:3篇
19MOL NEUROBIOL------------论文:3篇
20PHYTOMEDICINE------------论文:3篇
21ACTA PHARM SIN B------------论文:3篇
22BIOCHEM BIOPH RES CO------------论文:3篇
23CHINESE MED J-PEKING------------论文:3篇
24J CARDIOVASC PHARM------------论文:3篇
25FREE RADICAL BIO MED------------论文:3篇
26MOL CELL BIOCHEM------------论文:3篇
27PHARMAZIE------------论文:3篇
28FEBS LETT------------论文:3篇
29INFLAMMATION------------论文:2篇
30AUTOPHAGY------------论文:2篇
31EUR J MED CHEM------------论文:2篇
32XENOBIOTICA------------论文:2篇
33CELL BIOCHEM BIOPHYS------------论文:2篇
34CIRCULATION------------论文:2篇
35TOXICOL LETT------------论文:2篇
36J CELL BIOCHEM------------论文:2篇
37LIFE SCI------------论文:2篇
38J MOL CELL CARDIOL------------论文:2篇
39ACS CHEM BIOL------------论文:2篇
40J MED CHEM------------论文:2篇
41NEUROCHEM RES------------论文:2篇
42FASEB J------------论文:2篇
43CAN J PHYSIOL PHARM------------论文:2篇
44ANN HEMATOL------------论文:2篇
45ARTERIOSCL THROM VAS------------论文:2篇
46MED RES REV------------论文:2篇
47BRAIN RES------------论文:2篇
48ACTA PHYSIOL------------论文:2篇
49INT J MOL SCI------------论文:2篇
50J NEUROIMMUNOL------------论文:2篇
51CELL COMMUN SIGNAL------------论文:2篇
52J CELL MOL MED------------论文:2篇
53ONCOTARGET------------论文:2篇
54ATHEROSCLEROSIS------------论文:2篇
55PHARMACOLOGY------------论文:1篇
56MEDIAT INFLAMM------------论文:1篇
57MOL PHARMACOL------------论文:1篇
58J PROTEOME RES------------论文:1篇
59J CHEM INF MODEL------------论文:1篇
60EXPERT OPIN THER PAT------------论文:1篇
61INT IMMUNOPHARMACOL------------论文:1篇
62BIOSENS BIOELECTRON------------论文:1篇
63CELLS-BASEL------------论文:1篇
64NEUROREPORT------------论文:1篇
65J BIOMED SCI------------论文:1篇
66BBA-MOL CELL RES------------论文:1篇
67CELL MOL LIFE SCI------------论文:1篇
68CANCER LETT------------论文:1篇
69CNS NEUROSCI THER------------论文:1篇
70J LIPID RES------------论文:1篇
71AGING-US------------论文:1篇
72J CELL SCI------------论文:1篇
73LIPIDS------------论文:1篇
74INT J CLIN EXP MED------------论文:1篇
75J PHARM PHARMACOL------------论文:1篇
76CARDIOVASC DIABETOL------------论文:1篇
77FRONT CELL DEV BIOL------------论文:1篇
78J BIOL CHEM------------论文:1篇
79HEPATOLOGY------------论文:1篇
80ARCH TOXICOL------------论文:1篇
81ECOTOX ENVIRON SAFE------------论文:1篇
82CAN J CARDIOL------------论文:1篇
83HYPERTENSION------------论文:1篇
84HEPATOL RES------------论文:1篇
85INT J MOL MED------------论文:1篇
86INDIAN J CHEM B------------论文:1篇
87CELL SIGNAL------------论文:1篇
88J PHARM PHARM SCI------------论文:1篇
89CLIN SCI------------论文:1篇
90SYNTHETIC COMMUN------------论文:1篇
91SENSOR ACTUAT B-CHEM------------论文:1篇
92CURR DRUG METAB------------论文:1篇
93TETRAHEDRON------------论文:1篇
94CHEM-BIOL INTERACT------------论文:1篇
95CALCIFIED TISSUE INT------------论文:1篇
96N-S ARCH PHARMACOL------------论文:1篇
97ENDOCRINOLOGY------------论文:1篇
98RSC ADV------------论文:1篇
99MOL ENDOCRINOL------------论文:1篇
100J ETHNOPHARMACOL------------论文:1篇
您需要订阅学者后可以查看Email信息!
序号 名称
1liu, peiqing
2liu, pei-qing
3liu, p. q.
4liu, pei qing
5liu pei-qing
6liu, p. -q.
7liu peiqing
8liu, pq
1中山大学(2005-2020)
1. "全国药学专家学术影响力百强排名(2021年7月)"中排名第90位。

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.2亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-88110370

www.globalauthorid.com

TOP

Copyright © 2019-2021 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3